| Name | Ipratropium Bromide |
| Classes |
Dermatological/Topical Agent Respiratory Agent Antihistamine Nasal Preparation Antiasthmatic |
| Diseases |
Asthma Broncho Spasm Chronic Obstructive Pulmonary Disease (COPD) Emphysema Respiratory Disease |
Bangla
EnglishIpratropium Bromide
Ipratropium Bromide is a muscarinic antagonist. It works by blocking the interaction of acetylcholine to muscarinic receptor. Ipratropium is usually taken by oral inhalation route, as a result it blocks the muscarinic receptors present in the airways therefore opposing bronchoconstriction effect produced by acetylcholine and causing bronchodilation.
Ipratropium Bromide is is indicated for the treatment of bronchospasm associated with-
- chronic obstructive pulmonary disease (COPD)
- chronic bronchitis
- emphysema
- asthma
- cold and flue
Ipratropium is for oral inhalation only. The recommended dosage is two inhalations four times a day, not to exceed 12 inhalations in 24 hours.
Most common adverse reactions were-
- Bronchitis
- COPD exacerbation
- Dyspnea/ shortness of breath
- Headache
- Dizziness
- Dry mouth
- Sinusitis
- Not indicated for the initial treatment of acute episodes of bronchospasm where rescue therapy is required for rapid response.
- Hypersensitivity reactions including anaphylaxis: Discontinue Ipratropium at once and consider alternative treatments.
- Paradoxical bronchospasm: Discontinue Ipratropium and consider other treatments if paradoxical bronchospasm occurs.
- Ocular effects: Use with caution in patients with narrow-angle glaucoma and instruct patients to consult a physician immediately if signs or symptoms of narrow-angle glaucoma develop.
- Urinary retention: Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to consult a physician immediately if signs or symptoms of urinary retention develop.
Contraindication
- Contraindicated in patients with hypersensitivity to ipratropium bromide or any component of the medication.
- Contraindicated in patients with hypersensitivity to atropine or atropine derivatives-
None known.
None known.